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Abstract
Background: Leptin is an hormone that regulates body weight. Studies have shown increasing
leptin concentrations according to body mass index (BMI) and intermittent hypoxia.
Our aim is to evaluate the basal leptin levels in OSA patients and its possible relation to OSA
severity, independently of confounders and investigate the Autoadjusting-CPAP effect on leptin
values.
Methods: In ninety eight male patients with moderate to severe OSA leptin serum levels were
evaluated before therapy, 9 days and 6 months after therapy.
Results: In this group mean age was 55.3 years, mean BMI was 33.2 Kg/m2 and mean Apnoea-
Hypopnea Index (AHI) was 51.7/h. Mean basal serum leptin value was 12.1 ug/L. Univariate analysis
showed a significant correlation between serum leptin values and BMI (R = 0.68; p < 0.001), waist-
hip ratio (R = 0.283; p = 0.004) and AHI (R = 0.198; p = 0.048); in stepwise multiple regression
analysis only BMI (p < 0.001) was a predictor of serum leptin values.
One week after therapy, mean leptin serum level decreased to 11.0 ug/L and 6 months after it was
11.4 ug/L. (p = 0.56 and p = 0.387, respectively)
Conclusion: Baseline leptin serum levels positively correlate with BMI, fat distributioand OSA
severity.
BMI is the only predictor of basal leptin levels.
Treatment with Autoadjusting-CPAP has a small effect on leptin levels.
Background
Obstructive Sleep Apnoea (OSA) is a common disorder
with a prevalence of 2% to 4% in middle-aged adults [1].
The association between obesity and OSA is strong and
well described. Obesity is a major risk factor for OSA,
which occurs in up to 50% of obese men [1-6]. In addi-
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tion, approximately 70% patients with OSA are obese [7].
It is known that every 10-Kg increment in body weight
increases OSA risk twofold [8].
Leptin is a hormone with well Known functions concern-
ing body composition, energy homeostasis and feeding
behavior in humans [9-11]. It is an 167-amino acids pep-
tide hormone produced predominantly in white adipose
tissue [9-11]. Leptin circulates in the plasma in a free-form
state or bound to leptin-binding proteins [11]. It acts by
binding to specific receptors in the hypothalamus to
decrease appetite and increase energy expenditure [9-14].
Leptin inhibits the synthesis of hypotalamic neuropeptide
y (NPY), a potent stimulator of food intake, furthermore,
downregulation of NPY increases sympathetic nervous
system outflow enhancing energy expenditure [9-18].
In fact, leptin informs the brain about the size of adipose
stores and has been thought to be the obesity hormone
regulator [10].
The dramatic weight reduction observed in ob/ob mice in
result to leptin administration, raised expectations that
human obesity might also be a leptin deficient state treat-
able with exogenous leptin administration [19,20]. How-
ever, unlike the tight relationship present between obesity
and serum leptin levels in mice, human obesity seems to
be associated with more possible derrangements from lep-
tin deficiency to leptin resistance [21,22].
Leptin levels increase exponentially with increasing body
weight [11,22,23] and previous studies [22,24,25] have
reported a significant correlation between measures of
body fat and circulating concentrations of leptin in adults.
Under experimental conditions, intermittent hypoxia
stimulates leptin production and a number of studies
have demonstrated that serum leptin levels are elevated in
OSA patients, independently of obesity [18,26-32] despite
some couldn't find that relationship when controlled for
body fat [12,33,34]. If OSA is truly associated with
increased leptin serum levels independent of obesity, the
causal link remains unclear. Rodent studies [35,36] pro-
vided evidence for a leptin influence in breathing stability,
and thus predisposing individuals to develop OSA. In
alternative, OSA may be a cause of elevated leptin serum
levels through the effects of hypoxemia, sleep fragmenta-
tion or heightened sympathetic activity. Data showing
leptin serum levels reduction after CPAP nocturnal usage
in OSA patients [32,34,37-41] reinforces this idea.
The present study was conducted to evaluate the basal
serum leptin levels in OSA patients and its possible rela-
tion to OSA severity. This study has also the purpose of
understanding the Autoadjusting-CPAP effect on leptin
circulating levels after short and long term treatment, as
this effect has not been outlined yet, and the automated
pressure can play a different role in leptin levels variation
than that of fixed CPAP. Thus we try to clarify the relation-
ship between leptin and sleep apneic activity, independ-
ently of confounders.
Methods
Study design
This trial was designed as a prospective study. All patients
gave written informed consent to participate in the trial.
The study protocol was approved by the Hospital Ethics
Committe and the study was performed in accordance
with the guidelines of the Declaration of Helsinki and its
current revision.
Subjects
One hundred and two male consecutive patients referred
for suspected sleep disordered breathing to our Sleep Dis-
ordered Breathing Clinic were included in the study,
between February 2005 and March 2006.
All patients presented moderate/severe OSA (AHI > 20/h)
confirmed by domiciliary sleep study.
Exclusion criteria were stablished previously: neoplastic
diseases, systemic inflammatory chronic diseases, active
infectious diseases, systemic long term corticotherapy and
female gender.
All but four patients concluded the study (n = 98). Those
who failed to conclude the protocol were due to Autoad-
justing-CPAP intolerance.
Study procedures
An overnight sleep study was performed using a five-chan-
nel recording device (Alphascreen; Vyasis). This device pro-
duces a computorized recording of variations in oronasal
airflow (measured by nasal cannula), body position, wrist
actimetry, pulse rate and arterial oxygen saturation (meas-
ured by finger pulse oximetry). The device estimates the
total sleep time from the wrist actimetry registry, eliminat-
ing those periods with high activity. It automatically cal-
culates the number of apnoeas plus hypopnoeas per hour
of estimated sleep time (automatic respiratory distur-
bance index) and it also provides information of desatu-
rations > 4% per hour of estimated sleep time and the
cumulative percentages of sleep time under 90% oxygen
saturation. In all cases, sleep technicians carried out a
manual analysis of the recordings, by counting apnoea
(events of airflow cessation lasting for at least 10 seconds)
and hypopnoea episodes (events of airflow reduction to
20 to 50% of the previously observed lasting for at least 10
seconds, joined with a 4% dip in oxygen saturation and/
or an arousal), dividing the total number of these epi-BMC Pulmonary Medicine 2008, 8:21 http://www.biomedcentral.com/1471-2466/8/21
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sodes by the sleep time in hours, thus obtaining the man-
ual apnoea/hypopnoea index (AHI) according to
established criteria [42].
Auto-CPAP therapy was prescribed to all patients with a
minimum pressure of 4 and a maximum pressure of 15
cmH20.
24-hour Ambulatory Blood Pressure (Spacelab, Inc 90207
Neural) was performed in all but 3 patients who refused
the examination as they considered the arm disconfort
intolerable.
Fasting morning venous blood samples were collected
between 8–10 a.m. before treatment, one week after and
finally 6 months after the treatment initiation.
Blood samples were immediately sent to the laboratory
for estimation of glucose and lipids, while a specimen of
clotted blood was centrifuged at 4000 g for 20 min for
serum, which was stored at -26°C in eppendorfs® until
leptin analysis was performed.
Serum leptin concentrations were measured in duplicates
with a highly sensitive radioimmunoassay [43] (Linco
Res; St. Louis MO). The sensitivity of this assay was 0,5 ng/
mL, the specificity was 100% and the interassay coeffi-
cient of variation was 4,6%.
Statistical Analysis
Data were analyzed using SPSS, release 14.0, and
described as mean values and their respective standard
deviation for normally, or as median values and corre-
sponding 25th and 75th centiles for clearly non-normally
distributed variables. Counts and proportions are
reported for categorical variables. Proportions were com-
pared using Chi-square test or Fisher's exact test whenever
appropriate. Means and mean differences of leptin levels
between the second and the first period of observations as
well as between the third and the first periods of observa-
tion were compared by ANOVA or by non-parametric
equivalent.
Linear multiple regression models were used to estimate
the magnitude of the association between leptin levels
and the studied determinants.
Results
Sample Characteristics
Table 1 summarizes the sample characteristics.
Table 2 shows the patients distribution according to Bray's
obesity categories [44].
During the 6 months of the study, patients couldn't loose
significant weight (mean baseline weight = 94.4 Kg; mean
final weight = 94.1 Kg; p = 0.545).
Table 3 summarizes sleep study information.
Habits and Comorbidities
In this population 42.5% patients were non-smokers;
39.6% former- smokers (> 1 year without smoking habits)
and 17.9% had active smoking habits.
Arterial Hypertension (AH) was found, according to 24-
hour ambulatory blood pressure results, in 47.2% cases,
being 2.8% nocturnal AH.
Congestive heart failure was present in 9.4% patients,
according to clinical symptoms and used medication. His-
tory of stroke, acute myocardial infarction (AMI) and
angina was present in 15.1%, 7.5% and 1.9% patients,
respectively.
Blood analysis showed that 75.5% patients had high
serum lipid values (total cholesterol > 2.00 g/L; LDL >
1.30 g/L; triglicerides > 1.50 g/L) and 34.9% showed glu-
cose intolerance (fasting glucose > 1.15 g/L; HgA1c > 6%).
Leptin
Leptin serum levels are showed in table 4.
Sixty percent of patients presented elevated basal leptin
levels. The maximum value was 56.0 ug/L. The patients
with elevated basal serum leptin levels had a higher BMI
Table 1: Characteristics of the study group
Study group
Age (years) 55.3 ± 10.7
BMI (Kg/m2) 33.2 ± 5.0
Waist-to-hip ratio 1 ± 0.1
Table 2: Patients distribution according to Bray's obesity categories
Class 0
(BMI: 20–25)
Class I
(BMI: 25–30)
Class II
(BMI: 30–35)
Class III
(BMI: 35–40)
Class IV
(BMI > 40)
Patients 3.8% 23.6% 36.8% 30.2% 6.7%BMC Pulmonary Medicine 2008, 8:21 http://www.biomedcentral.com/1471-2466/8/21
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than the others (p < 0,001) but did not present a central
fat distribution (p = 0.052).
Leptin levels decrease after short and long-term Auto-
CPAP therapy were not statistically significant.
Confounders analysis
We analyzed whether age, BMI, fat distribution (waist-hip
ratio), OSA severity (AHI, dessaturation index, minimum
02 saturation), serum lipids and glucose intolerance could
be correlated with basal serum leptin levels or not.
An univariate analysis showed a significant correlation
between serum leptin values and BMI (R = 0.68; p <
0.001), waist-hip ratio (R = 0.283; p = 0.004) and AHI (R
= 0.198; p = 0.048).
In stepwise multiple regression analysis only BMI (p <
0.001) was a predictor of basal serum leptin values and
AHI was not found to be significant.
Auto-CPAP compliance
Compliance with Auto-CPAP was good but it was not
related to leptin decrease (table 5). Pressure on 90%
nighttime decreased significantly during the study (mean
baseline p90 = 10.8 cmH20; mean final p90 = 10.1; p <
0,001) and the mean residual AHI was 2.7/h ± 1.7.
Discussion
Obesity is the major factor regulating circulating leptin
[24,25,45] which is also influenced by gender and age
[23,46].
In this study, the authors found a strong and highly signif-
icant positive correlation between obesity (BMI) and
serum leptin levels at baseline (p < 0.001) as others have
demonstrated [11,22-25,45,47].
Several previous studies have reported increased plasma
leptin levels in patients with OSA [29,37,42,48], however
the relationship between leptin and OSA is far from being
resolved mainly because the potential confounding role
of obesity.
We found that leptin levels are clearly elevated in OSA
patients (mean basal value = 12.1 ± 12.2 ug/L; men nor-
mal range: 3.8 ± 1.8 ug/L) but these levels do not correlate
with OSA severity when considering confounders as obes-
ity and fat distribution. In this study, after performing
multiple regression analysis, the BMI was the only predic-
tor of baseline leptin serum levels. Also, some authors
could not find correlation between the OSA severity and
the leptin values when corrected for obesity [12,33] but
others did [26-30]. The latter studies included lower
number of patients when compared to the former and we
could speculate about the importance of the sample mag-
nitude to acquire statistical significance in differences
encountered.
We found that Auto-CPAP reduced only marginally leptin
plasma levels both in short and long term treatment (6
months). This may seem in contrast with previous studies
that have generally shown that leptin levels decrease sig-
nificantly with CPAP [36-41,48], but these changes were
generally small in absolute amount and not very different
from those determined here. Furthermore, although clin-
ical and physiological efficacy of Auto-CPAP is equivalent
to fixed CPAP [18,32] and despite the conclusions of
numerous studies about Auto-CPAP efficacy [49-55] in
controlling respiratory events and hypoxemia that is pre-
sumably implicated in plasma leptin levels [18,32], we
cannot exclude that nighttime pressure variation with
Auto-CPAP can affect leptin levels in a different way than
fixed CPAP does.
In summary, taking all these observations into account
our findings suggest that the increased leptin levels
described so far in patients with OSA is mostly associated
with obesity and not with the disease itself or its severity;
accordingly short and long term treatment with CPAP has
a small effect on leptin plasma levels and Auto-CPAP ther-
Table 3: Sleep studies information
Study group
AHI 51.7 ± 21.3
Desaturation index 86.3 ± 5.3
Lowest 02 (%) 70.8 ± 9.7
Mean 02 (%) 86.3 ± 5.3
Table 4: Leptin serum levels
Basal One week after therapy 6 months after therapy
Leptin Serum Levels (ug/L) 12.1 ± 12.2 11 ± 10.7 11.4 ± 10.6
Leptin variation significance (p) according to baseline 0.56 0.387BMC Pulmonary Medicine 2008, 8:21 http://www.biomedcentral.com/1471-2466/8/21
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apy compliance is not related with the leptin values
decrease.
As our patients didn't demonstrate a significant weight
loss, this variable could not be studied as a potential influ-
encing factor in leptin levels.
Some characteristics of our study deserve comment.
In order to get a more homogenous sample in this study,
the authors decided not to include women because of gen-
der effect on serum leptin circulating values. Leptin serum
levels are significantly higher in pre- and post-menopau-
sal female when compared to male, even after correction
for differences in body composition [23,46]. This sexual
dimorphism is apparently due to estrogen and progester-
one effects and eventually to an androgen supressive effect
on leptin [44].
The authors do not consider the OSA diagnosis based on
a domiciliary sleep study a limitation of the present study
as this diagnosis tool has already been compared to poly-
somnography showing to be a viable, accurate, satisfac-
tory, useful and cost effective way of diagnosing OSA
[56,57].
The lack of a control group can be seen as a limitation of
this study. Nevertheless we could demonstrate that OSA
patients have elevated serum leptin levels and we could
establish a significant positive correlation between BMI
and leptin levels.
Conclusion
OSA patients show elevated serum plasma levels.
BMI constituted itself as the only predictor of baseline lep-
tin levels.
Short- and long-term Auto-CPAP therapy produces a
small and not significant reduction in plasma leptin lev-
els.
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